Elder Pharmaceuticals Peer Comparison

NSE: ELDERPHARM | BSE: 532322

₹38.00

₹1.80 (4.97%)

As on 12-Sep-2016IST

Market cap

₹78 Cr

Revenue (TTM)

₹633 Cr

P/E Ratio

P/B Ratio

0.1

Div. Yield

0 %

Edit

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	78	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	633	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-79.91	414.00	288.22	-371.81	387.35
Net Margin (%)	-12.35	11.23	14.79	-3.93	26.01
RoE (%)	-61.43	8.38	29.77	-3.85	25.18
Price to Earnings	--	78.49	103.71	--	69.57
Price-To-Book	0.12	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	1,008.91	4,830.36	41.58	--	76.11
Total Income	1,034.57	4,914.64	41.73	--	76.68
Total Expenditure	1,088.10	3,850.53	30.00	--	69.99
EBITDA	-79.19	979.83	11.59	--	6.12
Depreciation	36.13	139.92	3.35	--	0.80
EBIT	-115.31	839.91	8.24	--	5.32
Interest	275.63	83.35	2.34	--	1.58
Other Income	25.66	84.28	0.14	--	0.56
Exceptional Items	371.27	49.83	--	--	--
Profit before Tax	5.99	890.67	6.04	--	4.31
Provision for Tax	12.52	47.88	1.54	--	1.44
Profit after Tax	-6.53	842.79	4.50	--	2.86

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	773.35	3,581.47	44.83	--	10.77
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	515.08	1,161.18	10.36	--	1.29
Current Liabilities	999.77	1,743.20	21.34	--	26.33
Total Liabilities	2,288.20	6,622.02	76.53	--	38.71

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	1,364.20	3,266.10	51.75	--	7.38
Current Assets	924.00	3,355.92	24.78	--	31.01
Total Assets	2,288.20	6,622.02	76.53	--	38.71
Total Debt*	847.62	1,906.08	21.09	--	12.17
Net Current Assets	-75.77	1,612.72	3.44	--	4.68
Contingent Liabilities	157.84	267.40	4.70	--	--

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	1,175.41	1,476.29	6.29	--	-0.21
Cash Flow from Investing Activities	-56.05	-851.62	-5.46	--	-2.00
Cash from Financing Activities	-676.18	-601.32	-0.58	--	2.17
Net Cash Inflow / Outflow	443.17	23.35	0.25	--	-0.04

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	15.08	18.98	13.38	--	29.97
ROE (%)	-0.85	30.04	19.08	--	30.26
ROA (%)	-0.27	13.36	6.16	--	8.85
EBIT Margin (%)	-5.31	22.03	28.21	--	8.78
Net Margin (%)	-0.63	17.15	10.78	--	3.74
Cash Profit Margin (%)	2.92	20.32	18.86	--	4.81

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-38.54	-13.89	12.11	--	37.10
EBIT Growth (%)	-117.49	-49.66	21.82	--	30.95
Net Profit Growth (%)	-107.93	-46.64	58.36	--	39.55
EPS Growth (%)	-107.93	-56.04	58.36	--	39.55
Book Value Growth (%)	0.53	36.37	21.09	--	32.03

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	6.59	0.00	--	0.00
Price / Book Value	0.58	1.55	0.00	--	0.00
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	-13.97	5.73	3.52	--	2.02
Market Cap (₹ Cr)	446.78	5,016.58	0.00	--	0.00

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	1.10	0.54	0.47	--	1.13
Short term debt to equity ratio	0.34	0.06	0.23	--	0.84
Current Ratio	0.92	1.93	1.16	--	1.18
Quick Ratio	0.81	1.36	1.11	--	0.75
Interest Coverage	1.02	11.69	3.58	--	3.73

	Elder Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	16.42	9.96	33.85	--	17.81
Asset Turnover	0.42	0.77	0.57	--	2.35
Receivable days	101.58	54.33	106.93	--	58.46
Inventory Days	67.21	77.43	10.49	--	41.85
Payable days	61.48	120.43	213.33	--	91.25
Cash Conversion Cycle	107.30	11.32	-95.91	--	9.06

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.